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Decreased expression of T-cell NF-jB p65 subunit in steroid-
resistant nephrotic syndrome.
Background. Although the etiology of childhood nephrotic
syndrome is unclear, there is evidence to suggest an important
role for T cells in the pathogenesis. Steroid resistance is consid-
ered a poor prognostic sign but the mechanism of the resistance
is unknown. The study examined the potential role of T-cell nu-
clear transcription factors in the steroid resistance.
Methods. The expression of the nuclear transcription fac-
tors activating protein-1 (AP-1) and nuclear factor-jB (NF-
jB) as well as that of lymphokines interleukin (IL)-2, IL-4, and
interferon-gamma (IFN-c) were compared in T cells obtained
from normal subjects, children with steroid-sensitive nephrotic
syndrome (SSNS) and children with steroid-resistant nephrotic
syndrome (SRNS) before any treatment was given. Changes in
expression and binding of the nuclear transcription factors were
studied with electrophoretic mobility shift assay (EMSA) and
Western blot, whereas mRNA cytokine expression were evalu-
ated by enzyme-linked immunosorbent assay (ELISA)-linked
reverse transcription-polymerase chain reaction (RT-PCR).
Results. A significant decrease of the p65 subunit protein of
NF-jB but not in p50 was documented by both EMSA (N = 7)
and Western blotting (N = 5) in five of five SRNS patients but
not in control subjects or SSNS patients; there was a decrease
in mRNA expression as shown by ELISA-linked RT-PCR. In
contrast, there were no significant differences in AP-1 expres-
sion by EMSA. IL-2 mRNA level was higher in T cells from
SRNS patients than in T cells from either SSNS or control sub-
jects. IL-4 and IFN-c were equally decreased in both groups of
patients.
Conclusion. The results show differences in T cells between
untreated SSNS and SRNS patients. The decrease of NF-jB p65
subunit and up-regulation of IL-2 are potential mechanism of
glucocorticoid resistance in SRNS.
Steroid resistance, which is often associated with the
histologic picture of focal segmental glomerulosclerosis
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(FSGS), is considered a poor prognostic sign in child-
hood nephrotic syndrome. Steroid-resistant nephrotic
syndrome (SRNS) accounts for approximately 15% of
all end-stage renal disease (ESRD) in children [1], and,
for unknown reasons, the incidence appears to be rising
[2]. No proven therapy exists for SRNS.
Although the pathogenesis of childhood nephrotic syn-
drome is unclear, there is evidence to suggest that T cells
play an important role in both steroid-sensitive nephrotic
syndrome (SSNS) and SRNS [3–7]. Several studies have
shown functional abnormalities in T lymphocytes of pa-
tients with nephrotic syndrome [5, 6, 8]. Patients with
SSNS and SRNS have a decreased synthesis of IgM and
a diminished number of CD4+ cells during relapse [5]
as well as increased expression of interleukin (IL)-2 re-
ceptor [6]. In addition, patients with SRNS have a circu-
lating factor produced by lymphocytes that may induce
proteinuria [9, 10]. The disease recurs in the transplant
kidney in 30% to 40% of the patients with SRNS [11].
Nephrotic-range proteinuria may recur as early as hours
after transplantation. Early intervention with alkylating
agents and plasmapheresis is effective in the treatment
of posttransplant recurrence [11, 12]. Furthermore, ag-
gressive immunosupression decreases the capacity of sera
from these patients to injure the glomerular permeability
barrier, which strongly suggests the presence of a circu-
lating immune mediator [12].
If steroid response in nephrotic syndrome is the re-
sult of glucocorticoid action on T cells, then T cells from
patients with SSNS and SRNS should display some dif-
ferences. Specifically, one can hypothesize that T cells
in SRNS possess some suppressor activity against the
glucocorticoid receptor-induced intracellular signaling.
The concept of a competitive suppressor activity is sup-
ported by the finding that in some cases steroid resis-
tance can be overcome by treatment with very large doses
of intravenous glucocorticoids [13, 14]. There are sev-
eral potential mediators of T-cell resistance to glucocor-
ticoids. IL-2 and IL-4 induce glucocorticoid resistance
in cultured normal lymphocytes [15, 16]. Furthermore,
60
Aviles et al: Expression of T-cell NF-jB subunit in SRNS 61
transcription factors activator protein-1 (AP-1) and nu-
clear factor-jB (NF-jB), which are important in the
activation of many proinflammatory genes, have been re-
ported to interfere with glucocorticoid action on T cells
in asthma and cancer [17–22]. NF-jB consists of two sub-
units, p50 and p65, which normally translocate to the nu-
cleus as p50/p65 dimers after antigenic stimulation. The
role of these transcription factors as mediators of steroid
resistance in nephrotic syndrome has not been previously
examined. To study the potential mechanism for glu-
cocorticoid resistance in patients with SRNS, we deter-
mined the expression of transcription factors NF-jB,
AP-1, and IL-2, IL-4, and interferon-gamma (IFN-c) cy-
tokines in T cells from patients with SSNS, SRNS, and
from control subjects. The results demonstrate that T cells
from patients with SRNS have a decrease of the p65 sub-
unit of NF-jB, and elevated levels of IL-2 compared to
patients with SSNS.
METHODS
Subjects
Eight patients with SSNS, eight patients with SRNS,
and five control patients (admitted for elective surgery)
were studied. Blood samples from both groups of
nephrotic children were obtained before therapy was
initiated. The SSNS patients were either newly diag-
nosed or in relapse without steroid treatment for at least
1 month. All SRNS and the new-onset SSNS patients
were prospectively studied at presentation and hence
without knowledge of their subsequent steroid respon-
siveness. Nephrotic syndrome was defined as the pres-
ence of edema, proteinuria of at least 2.0 g/24 hours or
urine protein: creatinine ratio of at least 2.0 and hypoal-
buminemia (<2.0 g/dL). Steroid resistance was defined
as unremitting nephrotic syndrome despite a minimum
of 4 weeks of daily prednisone treatment with approx-
imately 2 mg/kg/day up to a maximum of 80 mg daily.
None of the patients were treated with cyclosporine or
tacrolimus (both can affect the expression of NF-jB).
Steroid responsive was defined as patients who went into
complete remission within 2 months of oral glucocorti-
coid. Control subjects were normal children admitted for
elective surgery. The age of the subjects ranged from 2 to
18 years without significant differences between the three
groups. After an informed consent, blood was obtained
from a peripheral vein. A total of 10 mL blood was drawn
from children weighting between 10 and 20 kg; 20 mL
was drawn from children weighing more than 20 kg. Be-
cause of the small sample size and variations in yield, it
was not possible to perform all the described assays on
every sample.
T-cell enrichment
All the experiments were done on peripheral mononu-
clear cells (PBMC). PBMC were obtained after a Ficoll/
Hypaque density gradient. CD4+ T-cell–enriched pop-
ulation was collected by immunomagnetic negative
selection using magnetic cell separation microbeads fol-
lowing the manufacturer instructions (Miltenyi Biotech,
Auburn, CA, USA). The purity of the T-cell preparation
was 90% to 95% as assessed by flow cytometry.
Electrophoretic mobility shift assay
The electrophoretic mobility shift assay (EMSA) was
employed to detect the activated transcription factors
AP-1 and NF-jB as previously described [23]. Because
this method is based on the binding of the transcrip-
tion factors to their specific DNA recognition sequences,
it is highly specific. Two micrograms of T-cell whole
cell extracts were preincubated in reaction buffer for
10 minutes at room temperature. A [32P]- labeled
oligonucleotide (100 ng) with the consensus sequences
for NF-jB/C Rel homodimeric and heterodimeric com-
plexes and AP-1 (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) was then added to the reaction mixture and
incubated for 20 minutes. The complexes were separated
on a 5% polyacrylamide gels that were dried and exposed
to autoradiography. To confirm the results observed with
EMSA, we performed competition (supershift) assays
[23]. Briefly, the protein samples were incubated with an-
tibodies against p65 and p50 subunits of NF-jB (Santa
Cruz Biotechnology). To demonstrate the specificity of
the reaction, an antibody against SP-1 was used as a non-
specific control.
The samples were then incubated with the specific
[32P] oligonucleotides and separated on a 5% polyacry-
lamide gel followed by autoradiography. The retarded
bands were detected by autoradiography and quantified
by densitometry. The band density measurements were
expressed as relative density units.
Protein quantification by Western blotting
Whole cell extracts were isolated from T cells using an
NP-40–based lysis buffer containing 50 mmol/L Hepes,
250 mmol/L NaCl, 0.1% NP-40, 5 mmol/L ethylene-
diaminetetraacetic acid (EDTA), 1 lg leupeptin, 2 lg
aprotinin, 0.5 mmol/L dithiothreitol (DTT), 2 mmol/L
phenylmethylsulfonyl fluoride (PMSF), 10 lg trypsin-
chymotrypsin, and 10 lg chymostatin. Sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
and Western blotting were carried out as previously de-
scribed from our laboratory [23, 24]. The protein samples
(20 lg each) were electrophoresed in 8% Tris-glycine
gels (Invitrogen, Carlsbad, CA, USA) and transferred
onto polyvinylidine difluoride (PVDF) membranes
by electroblotting. The membranes were blocked and
immunoblotted with antisera against the p50 and p65
subunits of NF-jB (Santa Cruz Biotechnology) at 1:200
dilution washed, and incubated with horseradish
peroxidase-conjugated antirabbit immunoglobulin
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(Amersham, Buckinghamshire, UK). A second set of
antibodies for p65 and p50 were used [25] to find out if
the absence of p65 was due to conformational changes
in the protein. X-OMAT films were used to obtain the
autoradiographs. The autoradiographs were scanned
and the optical density of each sample quantified by
densitometry. The band density measurements were
expressed as relative density units. Due to limited
amount of protein, only five patients with SRNS and
SSNS were compared with controls.
mRNA quantification by enzyme-linked immunosorbent
assay (ELISA)-linked reverse transcription-polymerase
chain reaction (RT-PCR)
Total RNA was isolated from T lymphocytes using the
Ultraspec RNA system (Biotecx Laboratories, Houston,
TX, USA), treated with Dnase I (Boehringer Mannheim,
Indianapolis, IN, USA), and reverse transcribed as previ-
ously described [26]. An ELISA-linked PCR kit (Roche,
Indianapolis, IN, USA) was used for the quantification
of the specific cDNA species following manufacturer’s
instructions. Briefly, glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) primers were added to each PCR
reaction as an internal control, and a digoxigenin la-
bel was incorporated into all amplicons by including
0.02 mmol/L digoxigenin-deoxyuridine triphosphate
(dUTP) in the PCR reaction mix. The labeled PCR prod-
ucts were then denatured and hybridized to their re-
spective biotinylated capture probes in aqueous solution,
followed by immobilization on streptavidin-coated mi-
crotiter plate. The bound hybrids were detected by
peroxidase-conjugated antidigoxigenin antibodies and
read by standard microplate reader. Preliminary exper-
iments were carried out to optimize the conditions for
each primer pair, including choosing a PCR cycle number
corresponding to the exponential phase of amplification.
All the results were normalized with GAPDH. Primers
for IL-2, IL-4, IFN-c, NF-jB p65, p50 and GADPH were
based on published sequences and GenBank.
Statistical analysis
Results are expressed as mean ± SEM. Comparisons
between SSNS, SRNS, and controls were done by anal-
ysis of variance (ANOVA) with Bonferroni post tests.
For comparisons between patients with SSNS and SRNS,
Student t test was used. The statistical significance was
defined as P < 0.05. GraphPad Prism 3.0 (GraphPad Soft-
ware, San Diego, CA, USA) was used for statistical anal-
ysis of the results.
RESULTS
Expression of AP-1 and NF-jB in T cells
Expression of AP-1 and NF-jB transcription factors
was determined by EMSA in whole T-cell cellular ex-
tracts. There was no difference in the expression of AP-1
in patients with SSNS and those with SRNS when com-
pared to controls (data not shown). As seen in Figure 1A,
T cells from control subjects and patients with SSNS ex-
hibit both the heterodimer p65/p50 and the p50/p50 ho-
modimer of NF-jB. In contrast, T cells from all SRNS
patients showed a complete absence of the p65/p50 het-
erodimer with only the p50/p50 homodimer present. The
results are depicted quantitatively in Figure 1B; the ex-
pression of p65/p50 heterodimers in patients with SRNS
was not significantly different from zero.
Supershift experiments using anti-p50 and anti-p65 an-
tibodies confirmed the presence of p65/p50 heterodimers
in SSNS and p50/p50 homodimers in SRNS (Fig. 2). In
the patients with SSNS, there is retardation in the migra-
tion of the p65/p50 bands when the samples are incubated
with antibodies against either the p65 (lane3) or the p50
(lane2) subunits of NF-jB. In patients with SRNS, only
the anti-p50 antibody retards the migration of the bands
corresponding to the p50/p50 dimers (lane 6).
This results confirm the specificity in the expression
of these nuclear transcription factors, since no changes
in the migration pattern were noted when the protein
samples were incubated with an antibody unrelated to
NF-jB (Fig. 2, anti-SP-1, lanes 4 and 8). The differences
in the expression of NF-jB subunits seen by EMSA were
confirmed by Western blot quantification of the protein
content. Western blots were performed using polyclonal
antibodies against NF-jB p65 and p50 subunits. Similar to
the EMSA experiments, the p65 subunit was significantly
decreased in patients with SRNS but was expressed in
SSNS patients (Fig. 3). Normal controls showed expres-
sion of both p65 and p50 (Fig. 3A). To rule out the possi-
bility that the results were due to conformational changes
in the subunit proteins, two different antibodies for p65
and p50 were used. The results with the second antibody
for p65 and p50 showed similar results with an absence
of the p65 in patients with SRNS (data not shown). PCR
ELISA was employed to assess whether the decreased ex-
pression of p65 subunit in SRNS patients was associated
with changes in the mRNA levels. As shown in Figure 4A,
a significant decrease in p65 mRNA expression was
present in patients with SRNS. The p50 subunit mRNA
expression was similar in patients with SRNS and SSNS
(Fig. 4B).
IL-2, IL-4, and IFN-c mRNA expression in T cells
The cytokines IL-2, IFN-c, and IL-4 play an essential
role on T-cell activation. IL-2 is a T-cell–derived cytokine
important in the regulation of lymphocyte proliferation
and immune response. IL-2 and IL-4 can induce steroid
resistance in T cells. IFN-c is another activator of inflam-
matory response and cellular immunity. The mRNA ex-
pression for the three cytokines was measured in patients
with SSNS and SRNS during relapse and compared to
controls.
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Fig. 2. Representative supershift assay for
nuclear factor-jB (NF-jB). In patients (N =
7) with steroid-sensitive nephrotic syndrome
(SSNS) (left panel) antibodies against the p65
and p50 subunit blocks or prevents the mi-
gration of NF-jB. In patients with steroid-
resistant nephrotic syndrome (SRNS) (N =
8) antibodies against the p65 subunit do not
prevent the migration of the NF-jB complex.
Antibody against SP1 was used as negative
control.
The mRNA levels of IL-2, IL-4, and IFN-c were mea-
sured by PCR ELISA in purified T cells without stim-
ulation. IL-2 mRNA was significantly increased (P <
0.05) in patients with SRNS when compared to patients
Fig. 1. Expression of p65/p50 dimers. (A) Electrophoretic mobility
shift assay (EMSA) for nuclear factor-jB (NF-jB) in T cells from one
normal control (lane 1) and from seven patients with steroid-sensitive
nephrotic syndrome (SSNS) (lanes 2 to 8) (left panel). Both p65 and
p50 subunits of NF-jB are present in all subjects, forming p65/p50 and
p50/p50 dimers. EMSA in T cells from one control and from eight pa-
tients with steroid-resistant nephrotic syndrome (SRNS) (right panel).
The p65/p50 dimer is not detected in SRNS patients. (B) Densitometry
for the expression of p65/p50 dimers for NF-jB by EMSA. The ab-
sorbance level corresponding to NF-jB from individuals on each group
of patients is shown.
with SSNS and controls (Fig. 5A). In contrast, the ex-
pression of IFN-c, which plays an important role in the
activation of many proinflammatory genes was equally
decreased in both groups of patients (Fig. 5C). IL-4
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expression was decreased in patients with SSNS and
SRNS when compared to controls but there was no sig-
nificant difference between the two nephrotic groups
(Fig. 5B).
DISCUSSION
A large body of evidence suggests that T cells par-
ticipate in the pathogenesis of nonhereditary idiopathic
nephrotic syndrome. Therefore, the response to glucocor-
ticoid treatment may involve the glucocorticoid receptor-
mediated signaling pathway in T cells. The basis of steroid
resistance in nephrotic syndrome is unclear. The present
study was based on the hypothesis that resistance to glu-
cocorticoid treatment is mediated by the activation of
transcription factors and the production of lymphokines
that initiate and sustain an inflammatory response medi-
ated in great part by T cells.
NF-jB subunits normally form multiple dimmers, in-
cluding the heterodimer consisting of the p65 and p50
subunits [27]. The important new finding in the present
study is the decrease of the NF-jB p65 protein and
the corresponding marked decrease in the p65 subunit
mRNA in SRNS. The expression of the p50 subunit was
similar in SSNS and SRNS patients. Since the blood sam-
ples were obtained before treatment, the absence of p65
subunit cannot be attributed to therapy. Similarly the
nephrotic state itself cannot be responsible for the find-
Fig. 3. p65 and p50 subunites of nuclear factor-jB (NF-jB). (A) West-
ern blot. T cells from both control subjects (lanes 11 and 12) and steroid-
sensitive nephrotic syndrome (SSNS) patients (lanes 1 to 5) express
both subunits. Only the p50 subunit is present in T cells from patients
with steroid-resistant nephrotic syndrome (SRNS) (lanes 6 to 10). (B)
Densitometry of p65 NF-jB in Western blots. Each point represents
the absorbance of the band that corresponds to the p65 complex on
electrophoretic mobility shift assay (EMSA) from the same exposure
of the experimental radiograph.
ing because both groups of patients were nephrotic at the
time of study.
NF-jB regulates the transcription of several genes in-
volved in inflammatory reactions [28, 29]. In nonstim-
ulated cells, NF-jB is retained in the cytoplasm of the
cell by the interaction with the inhibitor IjB [30]. Upon
cell stimulation, IjB is phosphorylated, ubiquinated, and
eventually proteolyzed. The activated NF-jB dimers can
then translocate to the nucleus where gene expression
is regulated, induced, or repressed. Studies with Cos-1
cells transfected with glucocorticoid receptors and dif-
ferent NF-jB dimers have demonstrated the importance
of the p65 subunit in the transrepression by glucocorti-
coid receptors. Only cells transfected with the p65/p50
heterodimer or p65 homodimer are sensitive to steroids.
Cells transfected with only p50 homodimers do not
respond to steroids [31]. Thus, the absence of p65 subunit
impairs the ability of glucocorticoid receptors to suppress
immune functions by inhibition of NF-jB transcriptional
activity. Cao et al [32] showed that patients with SSNS
in relapse have an increased expression of both p65/p50
heterodimers of NF-jB.They also showed a decreased in
the expression of NF-jB when patients with SSNS were
treated with dexamethasone [32]. They suggest that in-
hibition of NF-jB and AP-1 is the potential molecular
mechanism for the effect of glucocorticoids in children
with SSNS [32].
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Fig. 4. Quantification of nuclear factor-jB (NF-jB) subunits and IjB-
a mRNA in T cells from steroid-sensitive nephrotic syndrome (SSNS)
and steroid-resistant nephrotic syndrome (SRNS) patients by reverse
transcription-polymerase chain reaction (RT-PCR) enzyme-linked im-
munosorbent assay (ELISA). The mRNA levels are normalized to
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA. (A)
NF-jB p65 mRNA is significantly decreased in SRNS (P < 0.05).
(B) NF-jB p50 mRNA levels are similar in SSNS and SRNS. (C)
IjB-a mRNA levels are not significantly different between SSNS and
SRNS.
The functional interference of glucocorticoids with NF-
jB is mediated by the interaction with the transactivation
domain of p65 [22]. The absence of p65 NF-jB could
result in inability to suppress NF-jB by at least three
potential mechanisms. First, prevention of physical inter-
action between the glucocorticoid receptor and NF-jB
0.0
0.5
1.0
1.5
2.0
IL
-2
/G
AP
DH
A
P < 0.05
P < 0.05
SSNS SRNS Control
0.0
0.5
1.0
1.5
2.0
IL
-4
/G
AP
DH
B
SSNS SRNS Control
0.00
0.25
0.50
0.75
1.25
1.00
IF
N
γ-
G
AP
DH
C
SSNS SRNS Control
P < 0.05
Fig. 5. Quantification of interleukin (IL)-2, IL-4, and interferon-
gamma (INF-c) mRNA in T cells from steroid-sensitive nephrotic
syndrome (SSNS) and steroid-resistant nephrotic syndrome (SRNS)
patients by reverse transcription-polymerase chain reaction (RT-PCR)
enzyme-linked immunosorbent assay (ELISA). The mRNA levels are
normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
mRNA.
could lead to unrepressed NF-jB activity. Second, nu-
clear export of active NF-jB dimers could be impaired,
leaving more dimers available for DNA binding [28]. In
B lymphocytes, Tam, Wang, and Sen [28] showed that
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NF-jB dimers containing p50 subunit could lead to ineffi-
cient nuclear export when compared to those dimers con-
taining the p65 subunit. Third, the absence of p65 could
decrease NF-jB affinity for the glucocorticoid-induced
leucine zipper (GILZ), which normally inhibits NF-
jB nuclear translocation by binding to the p65 subunit
[29].
Our results also show that T cells of patients with both
SRNS and SSNS have increased IL-2 expression in re-
lapse as compared to normal controls. This finding is con-
sistent with two previous reports. An increased IL-2 level
in serum from children with SSNS and SRNS was also re-
ported by Lama et al [33]. Zachwieja et al [34] used flow
cytometry to demonstrate increased intracellular IL-2 in
lymphocytes from patients with SSINS in relapse. IL-2
has been implicated in the development of nephrotic syn-
drome. For instance, proteinuria can be induced in rats
injected with recombinant IL-2 [35], and the use of this
growth factor in cancer chemotherapy causes proteinuria,
which resolves after the medication is discontinued [36].
In our study, there was a higher IL-2 mRNA expression
in patients with SRNS. This could be a contributory fac-
tor in the poor response to oral steroids in patients with
SRNS since high IL-2 expression has been reported to
induce steroid resistance in lymphocytes [16]. The high-
est levels of IL-2 were noted in patients with SRNS, in
spite of the decreased NF-jB p65 subunit expression.
T cells from patients with systemic lupus erythematosus
[37] showed an absence of p65 in T cells with a decreased
expression of IL-2. The abnormalities in the expression
of p65 persisted after treatment with corticosteroids [37].
However, our patients have an increased expression of
IL-2.
The regulation of the IL-2 gene is complex and includes
multiple transcription factors such as NF-jB, nuclear
factor of activated T cells (NFAT), octamer 2 (OCT2),
AP-1, and cAMP responsive element binding protein
(CREB). Although we did not observe differences in
AP-1 expression, it is possible that the absence of NF-
jB p65 may affect IL-2 production. Interestingly, NF-
jB p65 has been associated with IFN-c gene regula-
tion. The p65/p50 heterodimers are transactivators of the
IFN-c gene, while p50/p50 homodimers act as repres-
sors [38]. We did not see any difference in IFN-c pro-
duction in peripheral T cells in those patients with both
groups having decreased expression when compared to
controls.
CONCLUSION
We have shown an absence of the p65 subunit as well
as an increased expression for IL-2 in T cells from pa-
tients with SRNS. Both of these findings may contribute
to the steroid resistance. Because the p65 expression ap-
pears to be a consistant finding at the protein and mRNA
level, it may offer a diagnostic tool for early identifica-
tion of nephrotic children who are unlikely to respond to
conventional glucocorticoid therapy.
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